Clariant Strengthens US Presence by Expanding Pharma Grade PEG Manufacturing

Business Strategy Clariant Strengthens US Presence by Expanding Pharma Grade PEG Manufacturing

2026-03-25 Source: Press release Clariant 1 min Reading Time

Related Vendor

Clariant is expanding its Clear lake facility site in Texas, USA to include manufacturing of pharmaceutical grade polyethylene glycol excipients specifically for its North American customers.

North Carolina/USA – Clariant is expanding its Clear Lake site to include excipient GMP-compliant manufacturing of pharmaceutical-grade polyethylene glycol (PEG) excipients, significantly improving their availability and reliability for North American customers, with extended reach to Latin America. The multi-phase expansion addresses critical industry priorities around supply-chain security, continuity, and responsiveness while demonstrating Clariant's long-term strategic commitment to the U.S. pharmaceutical market.

The Clear Lake facility represents Clariant's first U.S. manufacturing site dedicated to producing pharmaceutical-grade PEG excipients, marking a pivotal milestone in the company's healthcare growth strategy. By establishing regional production capabilities, Clariant is creating a more resilient, responsive supply chain infrastructure for pharmaceutical manufacturers across the region.

The Clear Lake facility will allow Clariant to deliver tangible operational benefits that directly support pharmaceutical customers' production planning and business continuity. Regional manufacturing translates to significantly shorter lead times, allowing customers to respond more quickly to market demands and reduce inventory carrying costs while offering a more competitive price value. Enhanced supply continuity provides the predictability that pharmaceutical manufacturers require for complex production schedules and regulatory compliance.

"This expansion strengthens our ability to provide reliable local supply and positions us as a true partner to the North American pharmaceutical industry," said Vaios Barlas, Head of Health Care at Clariant. "In addition to greater manufacturing capacity, we're fundamentally transforming how we serve our customers by bringing production closer to their operations and accelerating more responsive, collaborative relationships."

The Clear Lake facility upgrade and operations were designed to meet the pharmaceutical industry's most rigorous quality, safety, and regulatory expectations. Excipient GMP compliance ensures that all manufacturing processes align with international pharmaceutical excipient standards, providing customers with the documentation, traceability, and quality assurance required for regulated pharmaceutical production. Clariant's pharmaceutical-grade PEGs are registered in relevant pharmacopoeias and feature negligible toxicity profiles, making them suitable for a wide range of applications.

(ID:50797175)

Subscribe to the newsletter now

Don't Miss out on Our Best Content

Business E-mail

Please enter a valid mailadress.

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy. The consent declaration relates, among other things, to the sending of editorial newsletters by email and to data matching for marketing purposes with selected advertising partners (e.g., LinkedIn, Google, Meta)

Date: 08.12.2025

Naturally, we always handle your personal data responsibly. Any personal data we receive from you is processed in accordance with applicable data protection legislation. For detailed information please see our privacy policy.

Consent to the use of data for promotional purposes

I hereby consent to Vogel Communications Group GmbH & Co. KG, Max-Planck-Str. 7-9, 97082 Würzburg including any affiliated companies according to §§ 15 et seq. AktG (hereafter: Vogel Communications Group) using my e-mail address to send editorial newsletters. A list of all affiliated companies can be found here

Newsletter content may include all products and services of any companies mentioned above, including for example specialist journals and books, events and fairs as well as event-related products and services, print and digital media offers and services such as additional (editorial) newsletters, raffles, lead campaigns, market research both online and offline, specialist webportals and e-learning offers. In case my personal telephone number has also been collected, it may be used for offers of aforementioned products, for services of the companies mentioned above, and market research purposes.

Additionally, my consent also includes the processing of my email address and telephone number for data matching for marketing purposes with select advertising partners such as LinkedIn, Google, and Meta. For this, Vogel Communications Group may transmit said data in hashed form to the advertising partners who then use said data to determine whether I am also a member of the mentioned advertising partner portals. Vogel Communications Group uses this feature for the purposes of re-targeting (up-selling, cross-selling, and customer loyalty), generating so-called look-alike audiences for acquisition of new customers, and as basis for exclusion for on-going advertising campaigns. Further information can be found in section “data matching for marketing purposes”.

In case I access protected data on Internet portals of Vogel Communications Group including any affiliated companies according to §§ 15 et seq. AktG, I need to provide further data in order to register for the access to such content. In return for this free access to editorial content, my data may be used in accordance with this consent for the purposes stated here. This does not apply to data matching for marketing purposes.

Right of revocation

I understand that I can revoke my consent at will. My revocation does not change the lawfulness of data processing that was conducted based on my consent leading up to my revocation. One option to declare my revocation is to use the contact form found at https://contact.vogel.de. In case I no longer wish to receive certain newsletters, I have subscribed to, I can also click on the unsubscribe link included at the end of a newsletter. Further information regarding my right of revocation and the implementation of it as well as the consequences of my revocation can be found in the data protection declaration, section editorial newsletter.